Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASSET study: Empagliflozin vs sitagliptin on cardiac fat and function in type 2 diabetes
jRCTs031180240Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial in type 2 diabetes mellitus (T2DM), steatosis and cardiometabolic disease comparing Empagliflozin treatment group with Sitagliptin treatment group (2 arms). Primary endpoint: Pericardial fat change. Started May 2017; status: completed.
02
Drugs
empagliflozinsitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)steatosiscardiometabolic disease
Beyond the preview
Go deeper on jRCTs031180240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180240.